GlassScriptPhysician profile
Jonathan D Wilkerson
NPI 1235326737
$8,516.89
in general payments reported to CMS, 2019-2025
35 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $520 · 2021: $1,119 · 2022: $1,192 · 2023: $1,443 · 2024: $1,747 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,960 · Education: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.52 |
| Education | $746.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,317.56 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,252.18 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $1,007.70 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $872.66 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $428.01 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $417.51 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $366.99 | 2021-2025 | |
| Amgen INC. | $347.63 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Mallinckrodt Hospital Products INC. | $309.52 | 2020-2024 | Acthar |
| Akebia Therapeutics INC | $308.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $284.33 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $217.84 | 2019 | |
| Calliditas Therapeutics US INC. | $214.24 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $156.39 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $109.69 | 2020-2023 | Krystexxa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.05 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $90.01 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $87.99 | 2022-2023 | Jesduvroq, Benlysta |
| Ultragenyx Pharmaceutical INC. | $72.78 | 2020-2024 | Crysvita |
| Nxstage Medical, INC. | $70.76 | 2019 | |
| Kyowa Kirin, INC. | $65.29 | 2024-2025 | Crysvita |
| Lundbeck LLC | $64.27 | 2019-2020 | |
| Lilly USA, LLC | $58.37 | 2024 | Jardiance |
| Genzyme Corporation | $42.94 | 2019-2024 | |
| Genentech USA, INC. | $42.50 | 2019-2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $41.88 | 2019 | |
| Shield Therapeutics INC | $37.74 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $30.77 | 2021 | |
| Cormedix INC. | $20.49 | 2025 | Defencath |
| Tactile Systems Technology INC | $17.14 | 2020 | |
| Shire North American Group INC | $16.96 | 2019 | |
| Allergan, INC. | $14.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.52 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.89 | 2020 | |
| Strongbridge US INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wilkerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.